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Edited by Horst FeldmannAbstract For over a century, vaccines were developed accord-
ing to Pasteur’s principles of isolating, inactivating and injecting
the causative agent of an infectious disease. The availability of a
complete microbial genome sequence in 1995 marked the begin-
ning of a genomic era that has allowed scientists to change the
paradigm and approach vaccine development starting from geno-
mic information, a process named reverse vaccinology. This can
be considered as one of the most powerful examples of how geno-
mic information can be used to develop therapeutic interventions,
which were diﬃcult or impossible to tackle with conventional ap-
proaches. As the genomic era progressed, it became apparent
that multi-strain genome analysis is fundamental to the design
of universal vaccines. In the post-genomic era, the next challenge
of the vaccine biologist will be the merging of the vaccinology
with structural biology.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Louis Pasteur, who developed the ﬁrst vaccine against ra-
bies, established in 1881 the basic paradigm for vaccine devel-
opment, which included the isolation, inactivation and
injection of the causative microorganism. These basic princi-
ples have guided vaccine development during the twentieth
century. All existing vaccines are based on killed or live-atten-
uated microorganisms or subunits puriﬁed from the microor-
ganism such as toxins detoxiﬁed by chemical treatment,
puriﬁed antigens or polysaccharide conjugated to proteins
(Table 1). Vaccines produced following Pasteur’s principles
allowed the control and, in some cases, the eradication of
many important infectious diseases. Despite several successes,
the Pasteur’s approach to vaccine development took a long
time to generate vaccines against those pathogens for which
the solution was feasible, but failed to produce vaccines
for those bacteria and parasites that do not have obvious
immunodominant protective antigens or for as yet uncultiva-
ble microorganisms.
In the last decade genomics has revolutionized vaccine re-
search. Since the publication of the ﬁrst complete genome se-*Corresponding author. Fax: +39 0577 243564.
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doi:10.1016/j.febslet.2006.04.084quence of a living microorganism in 1995 [1], the rate of
genomic discoveries has grown exponentially. To date, more
than 300 bacterial species have been sequenced and analyzed,
including those of most major human pathogens [2]. New
DNA sequencing technologies are emerging [3,4] which will
likely enable faster DNA sequencing projects and further
expansion of genomic information. The study of genomes by
both computational and experimental approaches has signiﬁ-
cantly advanced our understanding of the physiology and
pathogenicity of many microbes and has provided insights into
the mechanisms and history of genome evolution [5]. While
genomic and genome-based technologies applied to viral, bac-
terial and parasite pathogens are important from a scientiﬁc
perspective, they also have signiﬁcant potential to aid in the
development of novel diagnostics, therapeutics and vaccines.
The new approach of the genomic era, to develop vaccines
starting from the genomic information rather than growing
the causative microorganism, was named reverse vaccinology
[6] and can be used for the development of vaccines against
pathogen for which the applications of Pasteur’s principles
have failed.
In the post-genomic era, pathogen genome sequencing ef-
forts have expanded in order to include multi-representatives
of the same species and this pan-genome approach has shown
tremendous potential for making vaccines that once might
have been impossible to design. This review will focus on re-
cent reports that have contributed to the discovery of novel
vaccine candidates providing the proof of concept of gen-
ome-based approaches such as DNA microarray analysis,
pan-genome investigation and proteomics (Fig. 1). A future
view of the vaccinology ﬁeld and its fusion with structural biol-
ogy will be also discussed.2. The pioneering work of Meningococcus B
The concept of reverse vaccinology was applied for the ﬁrst
time in the attempt to develop a vaccine against serogroup B
Neisseria meningitidis (MenB), the major cause of sepsis and
meningitis in children and young adults.
At the end of the 1990s it was apparent that a universal
meningococcal vaccine was beyond the reach of conventional
vaccinology for two reasons: ﬁrstly, the polysaccharide
which has been successfully used to make conjugate vaccines
against other meningococci serogroups [7] is not immunogenic
for serogroup B (and, indeed, is a potential cause of auto
immunity, having an identical structure to a self human anti-
gen), and secondly, protein-based vaccines have focused onblished by Elsevier B.V. All rights reserved.
Table 1
Diﬀerent approaches to vaccine design in the pre-genomic era: application of Pasteur’s principles
Type Description Advantages Drawbacks Examples
Killed
microorganisms
The causative agent is
inactivated by chemical
or physical treatments
Eﬃcacious  Some pathogens are diﬃ-
cult or almost impossible
to cultivate in a scalable
setting
 Regulatory authorities re-
quire high safety and
quality standards for all
new vaccine formula-
tions; obtaining approval
might be diﬃcult
Polio virus vaccine
(Salk)
Inﬂuenza vaccine
Rabies vaccine
Oral cholera vaccine
Live attenuated
microorganism
The causative agent is
live but it has lost the
ability to cause the
disease
Eﬃcacious, induce a
protective immune
response
As above Polio virus (Sabin)
Intranasal inﬂuenza
vaccine (cold adapted)
Measles, mumps and
rubella (MMR)
Subunit Vaccines contain
puriﬁed portions of the
causative agents
 There is no risk that
vaccines can provoke
the disease
 If recombinant form
of the selected com-
ponents are utilized,
the pathogen need
not be cultivated
The identiﬁcation of the few
protective components from
the pool of molecules present
in the pathogen is usually
complex and time consuming
Diphtheria toxoid
Tetanus toxoid
Pertussis toxoid
Hepatitis B vaccine
Subunit –
onjugated
A polysaccharide
component of the
causative agent is
chemically linked to a
protein carrier
The conjugated
polysaccharide that is
poorly immunogenic on
its own becomes
immunogenic
 Need to grow the patho-
gen in vitro to obtain the
capsule polysaccharide
 Capsule not always
immunogenic
 Too many capsule types
Haemophlius inﬂuenzae
Meningococcus A, C,
Y, W135
Pneumococcus
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tion against other strains except the one used to make the
vaccine.
In a ﬁeld where traditional technologies and Pasteur’s prin-
ciples had failed to supply a vaccine, the advent of genomics
was considered a logical and promising resource that could
lead to a vaccine. Therefore, the complete genome sequence
of a virulent MenB strain was determined using a shotgun
strategy in collaboration with The Institute for Genomic Re-
search (TIGR) [8].
Based on the concept that surface-exposed antigens are sus-
ceptible to antibody recognition and are therefore the most
suitable vaccine candidates, the complete MenB genome was
screened using bioinformatic algorithms in order to select
ORFs coding for putative surface-exposed or secreted pro-
teins. Genome mining allowed the prediction of approximately
600 novel vaccine candidates, 350 of which were then ex-
pressed in Escherichia coli and tested for their ability to elicit
protective immunity. This approach identiﬁed 28 novel protec-
tive antigens, some of which are conserved in a panel of strains
representative of the meningococcal population and are likely
able to induce immunity against all meningococcal isolates [9].
In essence, in less than 18 months, reverse vaccinology ap-
plied to MenB enabled the identiﬁcation of more vaccine can-
didates than had been discovered during the past 40 years by
conventional methods. The genome-derived vaccine candidates
were prioritized and a selection of them have been developed in
a formulation suitable for human use in order to evaluate their
ability to induce immune responses in human beings.The success of reverse vaccinology in the development of a
new protein-based vaccine against N. meningitidis indicates
that this approach is very powerful and implied that any fu-
ture vaccine discovery project would strongly beneﬁt from
taking genome information into account (Fig. 1). Indeed, fol-
lowing the approach described for MenB, other research
groups have recently used genome-based approaches to iden-
tify vaccine antigens against several human pathogens. Table
2 reports representative examples of genomes explored for
vaccine candidates. Other approaches that have recently writ-
ten new chapters in the reverse vaccinology concept are re-
ported in more detail below.3. The ﬁrst application of the pan-genome concept in vaccine
design: the GBS example
While the genome sequence of many diﬀerent bacteria has
been determined, rarely more than one or two isolates of each
species have been sequenced. While the genome sequence of a
single strain reveals many aspects of the biology of a species, it
fails to address how genetic variability drives pathogenesis
within a bacterial species and also limits genome-wide screens
for vaccine candidates or for antimicrobial targets to a single
strain.
The advantage of multiple genome analysis in vaccine design
is highlighted by the discovery of universal vaccine candidates
against Streptococcus agalactiae, group B Streptococcus
(GBS). GBS is the leading cause of illness and death among
Fig. 1. The vaccinology ﬁeld. Past: Conventional approaches to produce vaccines are based on the cultivation of the microorganism in laboratory
conditions from which single components are isolated individually by using biochemical, microbiological and serological methods. Each antigen is
produced in pure form either directly from the bacterium or using the recombinant DNA technology, and ﬁnally tested for its ability to induce an
immune response. However, although successful in many cases, this approach presents several limitations. This approach needs to grow the pathogen
in vitro, so it is not applicable to uncultivable microorganisms, and in many cases the antigens expressed during infection are not produced in
laboratory conditions. Moreover, the proteins that are most abundant and easily puriﬁed are not necessarily protective antigens and, in any case,
only a few molecules can be isolated and tested simultaneously. In conclusion, this method can employ many years to identify a protective and useful
antigen, and has failed to provide a vaccine against those pathogens that did not have obvious immunodominant protective antigens. Present: The
genomic era has completely changed the way to design vaccines. The availability of the complete genome of microorganisms combined with novel
genome-based approaches (proteomic and microarray analysis) has introduced new perspectives in vaccine research. For the ﬁrst time, the genome
sequences represent an inclusive virtual catalogue of all the potential vaccine candidates from which it is possible to select the molecules that are likely
more eﬀective, regardless of their abundance, or if they are expressed in vivo or in vitro conditions. Pan-genome approach represents an advance in
the use of reverse vaccinology, since it highlights the potential of looking at more than one genome for the same bacterial species to overcome the
problems represented by gene presence and variability. Future: The structural biology applied to vaccinology (structural vaccinology) might give a
tremendous help in the development of vaccines against diseases that we could not defeat using other approaches. Structural biology studies will
allow the atomic resolution of the structures of potential antigens and, through the structure, the rational design of target epitopes to use as vaccine
candidates.
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have been described; however, the major disease-causing iso-
lates in Europe and US belong to only ﬁve serotypes: Ia, Ib,
II, III and V. Work on GBS vaccines has primarily focused
on the capsular carbohydrates but, unfortunately, antibodies
against any of these fail to confer protection against the others
[11].
A genomic approach to identify candidate vaccines against
GBS was conducted determining the complete genome se-
quence of a virulent GBS strain [12]. However, DNA micro-
array analysis revealed that there was a great deal of
variation in gene content among clinical isolates of GBS [12].
From this analysis it was clear that only one genome sequence
was not enough to develop a universal vaccine against GBS.
Hence, in order to explore gene variability within the GBS
species, Tettelin et al. determined the complete genome se-
quence of a type I strain and draft genome sequences of ﬁveadditional strains, representing the ﬁve major serotypes. Com-
parative analysis of the newly sequenced genomes, together
with two genomes already available in the databases, revealed
that a bacterial species can be described by its ‘‘pan-genome’’,
which includes two subgenomes: a ‘‘core genome’’ containing
genes present in all strains and a ‘‘dispensable genome’’ com-
posed of genes absent from one or more strain and genes that
are unique to each strain [13]. In general, the core genome in-
cludes all genes responsible for the basic aspects of the biology
of a given species. In contrary, dispensable genes are responsible
for species diversity and might encode additional biochemical
pathways and functions that can confer selective advantages,
such as antibiotic resistance or colonization of the host [14].
Maione et al. have applied the pan-genome concept to GBS
vaccine discovery [15]. Bioinformatic algorithms were used to
select genes from the two subgenomes that encode putative
surface-associated and secreted proteins. Among the identiﬁed
Table 2
Examples of genomes that have been explored for vaccine components using genome-based approaches
Pathogen Disease Brief description of the approaches References
Neisseria meningitidis B Major cause of bacterial
septicemia and meningitis
Reverse vaccinology, microarray – see text for details [9,26]
Streptococcus pneumoniae Most common cause of fatal
community-acquired pneumonia
in the elderly and is also one of
the most common causes of
middle ear infections and
meningitis in children.
Reverse vaccinology: all the ORFs of the genome sequence of a
clinical isolate of S. pneumoniae were evaluated to determine
whether the gene products contained sequence motifs predictive of
their localization on the surface of the bacterium. This led to the
identiﬁcation of 130 ORFs. Mice were immunized with 108 of these
proteins and 6 were shown to confer protection against
disseminated S. pneumoniae infection. All the 6 protective antigens
were broadly distributed among several pneumococcus strains and
showed immunogenicity during human infection
[44]
Comparative genomics: the genome of an avirulent strain (R6) of
S. pneumoniae has been sequenced. Comparative genome
hybridization using DNA arrays reveled diﬀerences between the
genomes of avirulent and virulent S. pneumoniae, which could
contribute to diﬀerences in virulence and antigenicity. This
comparison might lead to the identiﬁcation of some speciﬁc
proteins as potential target for vaccine development
[45]
Staphylococcus aureus Infects wounds and causes
severe infections. Following
acquisition of resistance to most
available antibiotics has
emerged as an important
opportunistic pathogen.
Genomic peptide libraries: S. aureus peptides were displayed on the
surface of E. coli via fusion to one or two outer membrane proteins
(LamB and FhuA) and probed with sera selected for high
antibodies titers and opsonic activity. The exhaustive screening of
these libraries by magnetic cell sorting determines the proﬁle of
antigens, which are expressed in vivo and elicit an immune
response in humans. A total of 60 antigenic proteins were identiﬁed
[46,47]
Serological proteome analysis: A surface proteins preparation from
S. aureus was resolved by 2D electrophoresis and analyzed in
immunoblotting using two pools, each consisting of ﬁve sera
coming from healthy donors or patients. Twenty-one spots were
isolated analyzed in mass spectrometry allowing the identiﬁcation
of 15 proteins including known and new vaccine candidates
[31]
Porphyromonas gingivalis Periodontal pathogen that has
been implicated in the etiology
of chronic adult periodontitis
Reverse vaccinology: applying a series of bioinformatics tools 120
putative new antigens have been identiﬁed from the genome of P.
gingivalis. The selected genes were cloned and expressed in E. coli
and screened by Western blot using sera from human periodontitis
patients. These candidates were reduced to a set 40 proteins, which
were puriﬁed and used to immunized mice that were subsequently
challenged with live bacteria in a subcutaneous abscess model. Two
antigens demonstrated protection in this model of infection and
therefore could represent potential vaccine candidates
[48]
Streptococcus agalactiae
(Group B streptococcus)
Leading cause of bacterial
sepsis, pneumonia and
meningitis in neonates in US
and Europe
Proteomics: Proteome analysis of the outer surface proteins of this
pathogen allowed the discovery of novel surface proteins. Sera,
raised against some of these proteins were protective in a neonatal
animal model against a lethal dose of the pathogen
[49]
Reverse vaccinology – see text for details [12,15]
Streptococcus pyogenes
(Group A streptococcus)
Causes many human infections
ranging from mild pharyngitis to
severe diseases, including toxic
shock syndrome, necrotizing
fasciitis and rheumatic fever
Comparative genomics: Analysis of the genome of four GAS strains
led to the discovery of four new extracellular proteins. These
proteins are very well conserved as observed applying sequencing
and genetic population analysis. Western immunoblot conﬁrmed
that all four proteins are made during the course of distinct GAS
infections and immunization with the puriﬁed form of one of these
can confer protection in a murine model of infection
[50,51]
Surface proteome – see text for details [32]
Chlamydia pneumoniae Causes pneumonia and is also
associated with atherosclerotic
and cardiovascular disease
Reverse vaccinology, proteomic: As a result of in silico analysis of C.
pneumoniae genome, 157 putative surface-exposed proteins have
been identiﬁed. Recombinant forms were expressed in E. coli,
puriﬁed and used to immunize mice. Antisera were used to detect
cell-surface localization by FACS analysis. 2D-gel electrophoresis
and mass spectrometry were used to conﬁrm the expression of the
FACS-positive antigens in the elementary body phase of
development. The result of these systematic genome-proteome
combined approaches allowed the identiﬁcation of 28 new vaccine
candidate antigens
[52]
Plasmodium falciparum Major causative agent of human
malaria
Post-genomic approaches: the availability of the genome of
Plasmodium falciparum, together with that of the vector Anopheles
gambiea and the human host provides for the ﬁrst time the entire
genomic information of the three living organisms whose
interaction is responsible for malaria. Kooij et al. reviewed several
post-genomic approaches recently undertaken, to develop vaccines
and drugs against this devastating infectious disease
[53,54]
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were variable genes. Authors were able to express soluble re-
combinant gene products in Escherichia coli from nearly half
of the identiﬁed genes and the corresponding puriﬁed proteins
were tested for protection against a GBS strain using an active
maternal immunization/neonatal pup challenge model. Four
antigens were capable of signiﬁcantly increasing the survival
rate among challenged infant mice. Only one of these antigens,
the Sip protein that had been previously identiﬁed as a poten-
tial vaccine antigen [16], was part of the core genome. Each of
the genes encoding the other three antigens was present in
approximately 75% of strains. When the four antigens were gi-
ven simultaneously as a vaccine, nearly universal protection
was observed against challenge with a panel of strains repre-
senting the major pathogenic GBS serotypes [15]. Levels of
protection were similar to that seen when using capsular car-
bohydrate-based vaccines [17].
Characterization of the newly identiﬁed vaccine antigens re-
vealed that one of them is able to form a pilus-like structure
extending from the bacterial surface [18]. This likely represents
an essential virulence factor of Gram-positive bacteria that has
been missed by conventional technologies for a century.
Eleven years after the ﬁrst bacterial genome sequence was
published, the pan-genome concept has shown that the initial
strategy of sequencing one or two genomes per species is not
suﬃcient and that multiple strains need to be sequenced to
understand the basics of bacterial species and to overcome
the problem represented by gene variability (Fig. 1).
The successful use of multi-strain genome analysis and the
screening described for GBS provides the basis for the poten-
tial development of universal protein-based vaccines against
other important and highly variable bacterial pathogens. Some
important examples are already reported: multiple genome
analysis was instrumental in discovering pilus-like structures
in group A Streptococcus (GAS) and S. pneumoniae [19,20].
Interestingly, GAS pili correspond to Lanceﬁeld T antigens
and have been unsuspectingly used during more than ﬁve dec-
ades to characterize GAS isolates. Moreover, immunization of
mice with a combination of recombinant pilus proteins confers
protection against mucosal challenge with virulent GAS bacte-
ria, underling the key role of pili for infection. The data indi-
cate that induction of a protective immune response against
these structures may be a useful strategy for development of
a vaccine against disease caused by GAS infection [19].
Regarding S. pneumoniae pili, Barocchi et al. showed that pi-
lus-like structures (present in some but not all clinical pneumo-
coccal isolates) are important for pneumococcal adherence to
lung epithelial cells as well as for colonization, pneumonia
and bacteremia in a murine model of infection. In addition, pi-
lus-expressing pneumococci evoke higher TNF response dur-
ing systemic infections than nonpiliated mutants. These data
highlight the pneumococcus pili as an important factor in col-
onization and in the severity of disease [20].4. Genome-based approaches: proteomic and microarray in
vaccine design
4.1. Microarray analysis
Global genomic proﬁling of gene expression using ordered
DNA or oligonucleotide microarrays has become in the last
few years a very powerful technology, which has revolution-ized the study of genes that are involved in microbial patho-
genesis.
Microarray analysis has been used to genotype bacteria,
viruses and parasites via comparative genome hybridization
(CGH). CGH involves the use of a microarray containing
DNA from a sequenced reference microorganism. These ar-
rays can be used to compare genomes of diﬀerent unsequenced
isolates by detecting genes that are conserved between them.
However, this highlights one intrinsic technical limitation of
microarray: detection is limited to the DNA spotted on the ar-
ray. This method also fails to detect acquisition events with re-
spect to the reference strains.
Alternatively, microarrays can be used to study gene expres-
sion. In this case they are hybridized with cDNA prepared
from mRNA isolated from microorganism grown under diﬀer-
ent growth conditions (for example in vivo versus in vitro
growth). Researchers are using microarray technology to iden-
tify genes that are diﬀerently expressed in response to alter-
ation in environmental parameters and to evaluate mutations
or key factors in regulatory and metabolic pathways. Another
purpose is to capture the transcriptome of bacteria growing
within infected cells, tissues or animal models (for review see:
[21–24]). Gene expression can be analyzed in either pathogen
or host, thus allowing investigation of both sides of the
host–pathogen interaction [25].
For vaccine discovery programs it is of key importance to
know what genes are expressed during host infection. In fact,
proteins that are expressed during disease represent the most
likely protective vaccine components. The ﬁrst example where
microarray technology was successfully used to identify poten-
tial vaccine candidates, as well as new virulence genes, was in
the case of N. meningitidis, where DNA microarray technology
was used to study gene regulation after interaction of N. men-
ingitidis to human epithelial cells [26]. RNA was isolated from
adherent and non-adherent bacteria and comparatively ana-
lyzed on DNA microarrays carrying the entire collection of
PCR-ampliﬁed meningococcus B genes. The authors found
that bacterial adhesion to epithelial cells altered the expression
of approximately 350 genes: 189 genes were upregulated and
151 genes were downregulated. Most of the regulated genes
can be grouped into ﬁve major categories: adhesion genes,
host–pathogen cross-talk genes, amino acids and selenocysteine
biosynthesis genes, DNA metabolism genes and hypothetical
genes. Moreover, of the 12 adhesion induced surface-exposed
antigens identiﬁed, ﬁve were able to induce bactericidal anti-
bodies. It is of interest to note that none of the 12 genes identi-
ﬁed by transcriptional proﬁling were identiﬁed by in silico
mining of strain MC58. In conclusion, this study shows that
DNA microarray technology is able to identify potential vac-
cine candidates and complement other genome mining methods
such as reverse vaccinology.
4.2. Proteomic analysis
While the availability of the complete genome sequence per-
mits the identiﬁcation of all potential protein products, this
information is not suﬃcient to allow the identiﬁcation of the
subset of proteins (the proteome), which are actually expressed
at any stage of the life of the bacteria in particular compart-
ments or under diﬀerent growth conditions. Recently, advances
in protein separation technologies, combined with mass spec-
trometry and genome sequencing, have made the elucidation
of total protein components of a given cellular population a
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with serological analysis has recently led to the development of
a new valuable approach deﬁned as serological proteome anal-
ysis (SERPA) for the identiﬁcation of in vivo immunogens suit-
able as vaccine candidates (Table 2, [30,31]).
An attractive and powerful application of proteomics, was
recently described by Grandi and colleagues who analyzed
the surface proteome of Streptococcus pyogenes (Group A
Streptococcus, GAS) to identify new vaccine candidate
proteins [32].
This new approach, consisting of the surface digestion of live
bacteria with diﬀerent proteases, allowed fast and consistent
identiﬁcation of proteins that are expressed on the bacteria
surface and thus exposed to the immune system. The cell-sur-
face peptide fragments generated after protease treatment of
GAS strain SF370 were recovered, concentrated and analyzed
by tandem mass spectrometry and identiﬁed using bioinfor-
matic examination of the publicly available genome sequence.
Seventy-two proteins were identiﬁed, of which only four were
predicted by the PSORT algorithm to be cytoplasmic proteins
indicating that the method was highly speciﬁc for surface-ex-
posed proteins. The power of this proteomics-based approach
to recover surface proteins with exposed domains was con-
ﬁrmed by FACS analysis. Mouse polyclonal antibodies were
produced against 51 recombinant proteins selected from the
surface-exposed, and 43 of these gave a positive result in the
FACS assay, conﬁrming the surface exposure of the proteins.
Considering that 7 of the 11 reported GAS protective antigens
were part of the surface proteome, the authors decided to
investigate whether some of the proteins identiﬁed could elicit
protective responses in a mouse model of infection. To do this,
they ﬁrst deﬁned the cell-surface proteins of serotype M23
strain DSM2071, a GAS strain that, unlike SF370, is highly
virulent in the mouse model. Seventeen proteins were identiﬁed
in this virulent strain, all of which have a homologue in strain
SF370. Of the 17 proteins identiﬁed, 14 were expressed in
E. coli as recombinant forms and used to immunize mice.
Intranasal challenge of the immunized mice with a lethal dose
of strain DSM2071 revealed that two of the proteins conferred
protection in this model: the M protein and a putative cell
envelope proteinase. M protein has been known for decades
to be a protective antigen, while the protective activity of the
putative proteinase was never been reported before [32].
The proteomic analysis of bacterial membranes is a key step
towards the resolution of membrane proteins: it supplies exper-
imental support to in silico prediction of protein compartmen-
talization and allows investigation of new aspects of the
topological organization of prokaryotic membranes. From a
vaccine point of view, a reliable list of surface-exposed proteins
oﬀers the possibility to identify and screen additional antigens
for their capacity to elicit a protective immune response.5. Looking at the future of vaccinology: the structural approach
The explosion of genome sequence and protein sequence
data has led to the growth of the ﬁeld of structural genomics,
a high-throughput application of structural biology, which uti-
lizes X-ray crystallography or nuclear magnetic resonance
(NMR) spectroscopy for determination of protein structure
or folding.Structural biology studies in the past few decades have al-
lowed the identiﬁcation and understanding of many basic prin-
ciples of proteins, nucleic acid structures, molecular machines
and viruses. Besides, structural biology demonstrated to have
enormous biomedical applications; indeed structure-based
development of therapeutics is already well integrated into
the pharmaceutical industry and lead to the identiﬁcation of
important drugs directed at the active sites of enzymes [33]
such as the inhibitors for HIV-1 protease [34] and inﬂuenza
virus neuraminidase [35].
We believe that structural biology can also signiﬁcantly aid
the rational design of future vaccines. Following the paradigm
that in order to defeat the enemy, one must ﬁrst know or even
better see the enemy, the application of structural biology prin-
ciples in the vaccinology ﬁeld may result in the creation of a
powerful new approach, the structural vaccinology (Fig. 1).
It will allow the atomic resolution of the structures of potential
antigens and, through the structure, the rational design of tar-
get epitopes to use as vaccine candidates.
Several examples of the application of structural biology to
the design of eﬀective vaccines are already in place against
pathogens that most heavily aﬄict global health, HIV and
Mycobacterium tuberculosis.
For HIV, structural and antigenic characterizations of the
virus envelope have allowed the discovery of unique mecha-
nisms that the virus possesses for evading the host antibody re-
sponse. Nabel and co-authors excellently reviewed the rational
design of an eﬀective AIDS vaccine applying structural infor-
mation [36]. HIV represents an evident example where the
structural vaccinology approach might be useful in the devel-
opment of a vaccine eliciting a broadly neutralizing response.
M. tuberculosis has recently become a model system for ini-
tiatives in structural genomics that resulted in solving the
structure of new potential drug targets and vaccine candidates
[37–39].
The antigen 85C (ag85C) story is an example of how basic
structural research can help in the development of an eﬀective
treatment for tuberculosis. Ronning et al. reported the X-ray
crystal structure of the M. tuberculosis ag85C protein (one of
the three components of the antigen 85 complex), which is
highly immunogenic (recognized by the immune system of in-
fected individuals) and was shown to play an important role in
cell wall synthesis and in ﬁbronectin binding [40,41]. The three-
dimensional structure sheds light on the regions of this antigen
that are responsible for ﬁbronectin binding and that may act as
epitopes. At the same time, the structure potentially allows the
rational design of peptide mimetics that promote antibody
production against surface-exposed sequences [42]. Antibodies
raised against the ag85C ﬁbronectin-binding peptide could
interfere with the ability of mycobacteria to interact with
and enter host macrophages. Therefore, epitopes based on
the ag85C ﬁbronectin-binding domain as well as other surface
exposed epitopes containing high sequence similarity between
the three ag85 homologues, could represent candidates for vac-
cine design [42].
The structural approach in vaccine design has also been ap-
plied to meningococcus. NMR spectroscopy was used to ob-
tain the solution structure of the immunodominant domain
of GNA1870, a protective antigen of N. meningitidis identiﬁed
by reverse vaccinology. Mapping of bactericidal epitopes on
the solved structure will help to predict the mechanism of im-
mune recognition. Moreover, the sequence similarity of
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family has allowed to predict the folding of this class of well
known bacterial antigens, providing the basis for the rational
engineering of high aﬃnity B cell epitopes [43].
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